7/102 sources · 2 publishersUpdated Nov 2, 21:51 UTC
CRISPR Therapeutics posts Q3 loss and revenue miss
CRISPR Therapeutics reported third‑quarter GAAP earnings of a $1.15 loss per share and revenue of $12.67 million. Both metrics fell short of analysts' expectations. The company said revenue rose sharply year‑over‑year, but the miss triggered a modest share decline. Analysts adjusted their EPS forecasts following the release.
Why it matters
The earnings and revenue shortfalls caused the stock to drop about 2% immediately after the announcement. Analysts have revised EPS estimates multiple times in response, indicating potential volatility in future guidance.
Key facts
- 1Q3 GAAP EPS was $‑1.15 per share. seekingalpha.com
- 2Revenue for the quarter was $12.67 million. seekingalpha.com
- 3Revenue missed the consensus estimate of $14.62 million. investing.com
- 4Revenue increased 1323.6% year over year. seekingalpha.com
- 5Shares fell 2% after the results were released. seekingalpha.com
- 6The stock is down 3.20% over the past three months and 19.38% over the past twelve months. investing.com
Open questions
- Material 1 says the EPS miss was $0.15, while material 2 says it was $0.11.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.